Zoledronic acid: A new parenteral bisphosphonate
- 1 November 2003
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 25 (11) , 2669-2708
- https://doi.org/10.1016/s0149-2918(03)80327-2
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple MyelomaJournal of Clinical Oncology, 2002
- Highly Potent Geminal Bisphosphonates. From Pamidronate Disodium (Aredia) to Zoledronic Acid (Zometa)Journal of Medicinal Chemistry, 2002
- Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitroBone, 2001
- Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studiesSeminars in Oncology, 2001
- The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxelBritish Journal of Cancer, 2001
- Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironmentSeminars in Oncology, 2001
- Bisphosphonates Induce Breast Cancer Cell Death In VitroJournal of Bone and Mineral Research, 2000
- Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298Journal of Bone and Mineral Research, 2000
- American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast CancerJournal of Clinical Oncology, 2000
- Bone metastases: pathophysiology and management policy.Journal of Clinical Oncology, 1991